A review on Late phase ischemic preconditioning.

*Arun Kr. Tiwari\(^1\), Dilip Kr. Patel\(^1\), Kaveri Devi\(^2\) and Ahsas Goyal\(^3\).

1. Chandra Shekhar Singh College of Phantom, Koilaha, Kausambi, Allahabad, (U.P.), India.
2. Venkateshwara School of Pharmacy, Meerut, U. P. India.
3. Institute of Pharmaceutical Research, GLA University, Mathura-281406, Uttar Pradesh, India.

**Abstract**

Ischemic preconditioning consists of brief episode of sub lethal ischemia followed by reperfusion. It is a biphasic phenomenon, which starts within minutes and get wanes off gradually within 2 to 3 hours and also called as classical preconditioning and the other phase which appear after 12-24 hours called as late phase of ischemic preconditioning (or delayed phase) which lasts up to 3 to 4 days also called as second widow of protection. Unlike the early phase of ischemic preconditioning, the late phase of ischemic preconditioning protects not only against the myocardial infarction but also include protection against myocardial stunning. Both these phases, early and delayed are responsible for the protection against myocardial infarction and myocardial stunning.

Late phase of ischemic preconditioning involves certain mechanisms that includes first one as those species which are generated during the starting ischemic insult and responsible for the activation of late preconditioning triggers. Second mechanism includes those which are activated after 24-72 hours of the ischemic insult and responsible for the activation of mediators of late preconditioning. The third one is activated by the action of triggers to show the actions of mediators. All these mechanism are in sequences, former is upstream signal for the next one and they were activated only after preconditioning stimulus. This phenomenon of ischemic preconditioning shows its benificial effect via involvement of certian triggers and mediators like COX-2, NO, Aldose reductase, etc.

The heart posses a notable capability to adapt stress by changing its phenotype which makes it more resistant to the injury and this remarkable ability is illustrated by the phenomenon of preconditioning (PC), it is the process whereby the tolerance of the myocardium is enhanced by the sublethal ischemic stress. Ischemic preconditioning is a effective strategy against heart from ischemia reperfusion injury (Murray et al. 1997). Ischemic preconditioning consists of brief episode of sub lethal ischemia followed by reperfusion (Tomai et al., 1999). It is a biphasic phenomenon, which starts within minutes and get wanes off gradually within 2 to 3 hours and also called as classical preconditioning (Downey and Cohen, 1997, Yellon and Downey, 2003) and the other phase which appear after 12-24 hours called as late phase of ischemic preconditioning (or delayed phase) which lasts up to 3 to 4 days also called as second widow of protection. Unlike the early phase of ischemic preconditioning, the late phase of ischemic preconditioning protects not only against the myocardial infarction but also include protection against myocardial stunning. Both these phases, early and delayed are responsible for the protection against myocardial infarction and myocardial stunning. Classical preconditioning include four 5 min- periods of coronary occlusion, interspersed with 5 min reperfusion before a global ischemia of 40 minutes occlusion of the same coronary artery (Marber et al., 1993).
There are various non pharmacological and pharmacological stimuli of delayed preconditioning which are responsible for the delayed protection against myocardial ischemia/ reperfusion injury. The former one include heat stress (Currie et al., 1988), rapid ventricular pacing (Kaszala et al., 1996) and exercise (Yamashita et al., 1999). The later one include naturally occurring and often noxious agents such as endotoxin (Brown et al., 1989), tumour necrosis factor-α [TNF-α] (Brown et al., 1989), TNF-β, interleukin-1 (Nelson et al., 1995), and drugs used for clinical purpose such as adenosine receptor agonists (Baxter et al., 1994), NO releasing agents (Takano et al., 1998), endotoxins derivatives like monophosphoryl lipid A [MLA] (Yao et al., 1993) and opioid agonists (Fryer et al., 1999).

Mechanism of late preconditioning:-
Late phase of ischemic preconditioning involves certain mechanisms that includes first one as those species which are generated during the starting ischemic insult and responsible for the activation of late preconditioning triggers (Bolli, 2000). Second mechanism includes those which are activated after 24-72 hours of the ischemic insult and responsible for the activation of mediators of late preconditioning. The third one is activated by the action of triggers to show the actions of mediators. All these mechanism are in a sequences, former is upstream signal for the next one and they were activated only after preconditioning stimulus (Bolli, 2000).

Initiators of late preconditioning:-
The brief episode of ischemia and reperfusion is responsible for the generation of wide variety of metabolites and ligands. Among these metabolites and ligands it was found that certain chemical signal such as nitric oxide [NO], adenosine, opioid receptor agonist are involve for the initiating the late phase of ischemic preconditioning (Bolli, 2000).

The concept that adenosine is involved in initiating the late preconditioning was first proposed by Baxter (Baxter et al., 1994) However the involvement of adenosine receptor in late preconditioning is under investigation. It was reported in previous studies that 2-chloro-NCPA-cyclopentyladenosine (CCPA) induced preconditioning which is highly selective for A1 is blocked by A1 antagonist (Takano et al., 1999). therefore it can be concluded that the agonist elicit delay cardioprotection by A1 receptor. Recent evidences had also suggested that the selective activation of A1 receptor is also playing an important role in initiating the delayed protection against infarction. Thus it can be concluded that the pharmacological activation of A1 and A3 receptor can elicit late precondition infarction (Bolli, 2000).

It was also demonstrated in various studies that NO is also an important factor that involves in initiating the ischemia induced by late preconditioning against myocardial infarction where exogenous NO can reproduce late preconditioning. It has also been reported that the biosynthesis of NO in myocardium will get enhanced during the brief episodes of ischemia (Qiu et al., 1997). Nitric Oxide (NO) play an important role in IPC and IPOC induced cardioprotection by activating cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG)-dependent signaling pathway. NO directly modify protein sulphydryl residues through protein S-nitrosylation (SNO), which has emerged as an important post-translational protein modification in cardiovascular signaling and produces cardioprotection (Murphy et al., 2004).

Moreover, it was also found that reactive oxygen species (ROS) also initiate the delayed phase of cardioprotection (Sun et al., 1999). It was supported by the fact that the combination of antioxidants (Superoxide dismutase + catalase + mercapropionyl glycine) had prevented the development of late preconditioning against stunning (Sun et al. 1999). However MPG alone involves in preventing the ischemia induced late preconditioning against infarction (Yamashita et al., 1998), arrhythmias (Yamashita et al., 1998), coronary endothelial injury, heat stress induced (Kaeffer et al., 1997; Yamashita et al., 1998).

Activation of δ- opioid receptors are also involved in inducing a delayed infarct sparing effect after 24-48 hours (Fryer et al., 1999; Guo et al., 2000).

Effectors of Late phase of Ischemic preconditioning:-
Late phase of preconditioning requires the synthesis of new protein. Several proteins have been proposed as the possible effectors of protection afforded by the late phase of precondition HSP, NOS, COX-2, Aldose reductase, and antioxidant enzymes (Bolli, 2000).
Nitric oxide plays dual role in late preconditioning against stunning acting initially as the triggers and subsequently as the mediator of the protection. Bolli and his coworker has implicated that the synthesis of nitric oxide (NO) is an important mediator of late phase of ischemic preconditioning (Tokano et al., 1997, Guo et al., 1999). There are three isoform of nitric oxide synthase (NOS) found in myocardium i.e. endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS). The activity of first two isoform of nitric oxide synthase are regulated by cytosolic concentration of calcium and by the presence of different co-factors like tetra hydrobiopterin (BH4), magnesium and NADPH. The activity of third isoform iNOS is calcium independent synthase and shown by protein transcription. The ischemic stress leads to upregulation of transcription factors such as NF-kB (Brown et al., 1989, Brown et al., 1990) and this protein transcription is responsible for the upregulation of iNOS and therefore responsible for the production of nitric oxide in delayed phase of preconditioning (Bolli, 2000). It has been reported by researchers that iNOS is the specific nitric oxide synthase responsible for the cardioprotective effect of late phase of ischemic preconditioning.(Takano et al., 1998).

The certain pathological conditions like ischemia, hypoxia, and oxidative stress are also responsible for the upregulation of cyclooxygensae-2 enzyme (Shinmura et al., 2000, Bolli et al., 2002). COX-2 protein will get upregulated after the 24 hours of ischaemic pc along with the increased myocardial levels of PGE2,6-keto-pgf1 and 2α. The necessity of COX-2 activity can be demonstrated by observed distruction of the increased prostanoids and the completely blockade of the cardioprotective effect of late PC after the administration of selective inhibitors of COX 2 (N-398 and colecoxib) after 24 hours of ischaemic preconditioning (Shinmura et al., 2000).

It has been documented that vascular endothelium is major source of COX-2 enzyme (Bryant et al., 1998, Schror, 2009). It was also documented that COX-2 is involve in the cardioprotective effect of late phase of ischemic preconditioning (Yadav et al., 2010). The cardioprotection produces by this enzyme is mediated by prostaglandin receptor i.e. PGI2 (Shinmura et al., 2002) and also by making a complex with the nitric oxide (NO) (Ajmani et al., 2011).

COX 2 protein will get upregulated after the 24 hours of ischaemic pc along with the increased myocardial levels of PGE2,6-keto-pgf1 and 2 alpha. The necessity of COX-2 activity can be demonstrated by observed distruction of the increased prostanoids and the completely blockade of the cardioprotective effect of late PC after the administration of selective inhibitors of COX 2 (N-398 and colecoxib) after 24 hours of ischaemic preconditioning.

Aldose reductase is as an enzyme which catalyzes the metabolism of glucose to sorbitol and also involves in the detoxification of lipid aldehydes derived from the reactive oxygen species (Srivastava et al., 1998). It has been found that the protein expression of aldose reductase will get up regulate after the 24 hours of ischemic pc in conscious rabbit (Shinmura et al., 2000). Thus it can be concluded that aldose reductase must be the third necessary mediator involved in the cardioprotective action of ischemic preconditioning, however the mechanism involved in it is remains unclear.

A study conducted on isolated neonatal myocytes had found that MnSOD an antioxidant enzyme is necessary for ischemia induced late PC. An increased level of MnSOD is observed after the 24 hours of ischaemic pc due to the production of ROS, TNF-α and interleukin - 1β. MnSOD induction is responsible for the increasing the Late phase of Ischemic preconditioning beneficial activity after the heat stress, exercise. The activity was seen to be increased by increasing the MnSOD due to the involvement of ROS, TNF-α and interleukin- 1β (Guo et al., 2000; Yamashita et al., 1999; Yamashita et al., 2000)

In the previous studies it has been reported that over expression of Heat shock protein (HSP) 70 in transgenic mice shows protection against ischemia/reperfusion injury. But, it was also in controversial that whether the pharmacological preconditioning or ischemic preconditioning up regulate the HSP-27 in-vivo. Since the HSP-27 is a substrate for the p38 nitrogen activated protein kinase pathway, which is activated after 24 hours of CCPA administration. Hence the HSP-27 is responsible for the post transitional modulation which play an important role in mediating the delayed cardioprotection is afforded by CCPA (Dana et al., 2000).

**Conclusion:-**

It was concluded that the pharmacological and cardioprotective activity of Late phase of ischemic preconditioning is due to involvement of certain initiators and mediators. The triggers of late phase of ischemic preconditioning includes Adenosine receptors including A1 and A3, Nitric oxide involving three nitric oxide synthase i.e. eNOS,
iNOS, and nNOS, Reactive oxygen species, and some opioids receptors like δ, opioid receptor. They all were reposable for triggering the late phase of ischemic preconditioning.

There are certain mediators which is responsible for the cardioprotective effect including NOS, cyclooxygenase-2 (COX-2), aldose reductase, antioxidants enzymes, and heat stress proteins.

References:
1. Ajmani, P., Yadav H.N., Singh, M., and Sharma, P.L. “Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart”, BMC Cardiovascular Disorders, vol.11, pp.43, 2011.
2. Brown JM, Gross MA, Terada LS, Whitman GJR, Banerjee A, White CW, Harken AH, Repine JE. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A. 1989;86:2516–2520.
3. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation. 1994;90:2993–3000.
4. Bolli, ”The late phase of preconditioning” Circ Res. 2000;87: 972-983.
5. Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW, Banerjee A, Whiteman GJ, Harken AH, Repine JE. Interleukin-1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 1990;87:5026–5030.
6. Brown JM, Anderson BO, Repine JE, Shanley PF, White CW, Grosso MA, Banerjee A, Bensard DD, Harken AH. Neutrophils contribute to TNF induced myocardial tolerance to ischaemia. J Mol Cell Cardiol. 1992;24:485–495.
7. Brown JM, Gross MA, Terada LS, Whitman GJR, Banerjee A, White CW, Harken AH, Repine JE. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemiareperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A. 1989;86:2516–2520.
8. Currie RW, Karmazyn M, Kloc M, Mailer K. Heat-shock response is associated with enhanced postischemic ventricular recovery. Circ Res. 1988;63:543–549.
9. Dana A, Skarlí M, Papakrivopoulou J, Yellon DM. Adenosine A1 receptor induced delayed preconditioning in rabbits: induction of p38 MAPK activation and Hsp27 phosphorylation via a tyrosine kinase and protein kinase C-dependent mechanism. Circ Res. 2000;86:989–997.
10. Downey, M and Cohen, M.V. “Preconditioning: What it is and How it Works”, Dialogues in Cardiovascular Medicine, vol.2, pp.179-196, 1997.
11. Fryer RM, Hsu AK, Eells JT, Nagase H, Gross GI. Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res. 1999;84:846–851.
12. Guo Y, Bao W, Tang X-L, Wu W-J, Takano H, Bolli R. Pharmacological preconditioning (PC) with adenosine A1 and opioid δ receptor agonists is iNOS-dependent. Circulation. 2000;102(suppl II):II-121.
13. Kaefler N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation. 1997;96:2311–2316.
14. Kasazala K, Vehg A, Papp JG, Parratt JR. “ Time course of the protection against ischemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing. J Mol Cell Cardiol, vol. 28, pp. 2085-2095.
15. Liu, G.S., Thornton, J., Van Winkle, D.M., Stanley, A.W., Olsson, R.A., Downey, J.M. “Protection Against Infarction Afforded by Preconditioning is Mediated by A1 Adenosine Receptors in Rabbit Heart”, Circulation, vol.84, pp.350–356, 1991.
16. Marber, M.S., Latchman, D.S., Walker, J.M. and Yellon, D.M. “Cardiac Stress Protein Elevation 24 hours After Brief Ischemia or Heat Stress is Associated with Resistance to Myocardial Infarction”, Circulation, vol.88, pp.1264-1272, 1993.
17. Murphy, E. “Primary and Secondary Signalling Pathways in Early Preconditioning that Converge on the Mitochondria to Produce Cardioprotection”, Circulation Research, vol.94, pp.7-16, 2004.
18. Murray, C.J.L. and Lopez, A.D. “Global mortality, disability, and the contribution of risk factor: Global burden and disease study”, Lancet, vol.349, pp.1436-1442, 1997.
19. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol. 1995; 27:223–229.
20. Qiu Y, Rizvi A, Tang X-L, Manchikalapudi S, Takano H, Jadoo AK, Wu W-J, Bolli R. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 1997;273:H2931–H2936.
21. Sun J-Z, Tang X-L, Knowlton AA, Park SW, Qiu Y, Bolli R. Late preconditioning against myocardial stunning: an endogenous protective mechanism that confers resistance to postischemic dysfunction 24 hours after brief ischemia in conscious pigs. *J Clin Invest.* 1995;95:388–403.

22. Shinmura K, Tang X-L, Wang Y, Xuan Y-T, Liu S-Q, Takano H, Bhatnagar A, Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. *Proc Natl Acad Sci U S A.* 2000;97:10197–10202.

23. Srivastava S, Chandra A, Wang L-F, Seifert WE, DaGue BB, Ansari NH, Srivastava SK, Bhatnagar A. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. *J Biol Chem.* 1998;273:10893–10900.

24. Takano H, Bolli R, Tang X-L, Yang Z, Black R, Auchampach J. Activation of A1 or A3 receptors produces delayed protection against infarction in conscious rabbits by a mechanism involving KATP channels. *Circulation.* 1999;100:1-56.

25. Takano H, Tang X-L, Qiu Y, Guo Y, French B, Bolli R. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. *Circ Res.* 1998;83:73–84.

26. Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. *European Journal Pharmacology,* vol.643, pp.78-83, 2010.

27. Yadav HN, Singh M, and Sharma PL. Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart. *Molecularand Cellular Biochemistry,* vol.343, pp.75-81, 2010.

28. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori MA. “Second window of protection” occurs 24 h after ischemic preconditioning in the rat heart. *J Mol Cell Cardiol.* 1998;30:1181–1189.

29. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori M. Whole-body hyperthermia provides biphasic cardioprotection against ischemia/reperfusion injury in the rat. *Circulation.* 1998;98:1414–1421.

30. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori MA. “Second window of protection” occurs 24 h after ischemic preconditioning in the rat heart. *J Mol Cell Cardiol.* 1998;30:1181–1189.

31. Yao Z, Auchampach JA, Pieper GM, Gross GJ. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. *Cardiovasc Res.* 1993;27:832–838.

32. Yellon, D.M. and Downey, J.M. “Preconditioning the Myocardium From Cellular Physiology to Clinical Cardiology”, *Physiological Research,* vol.83, pp.1113-1115, 2003.

33. Yamashita N, Hoshida S, Otsu K, Taniguchi N, Kuzuya T, Hori M. Involvement of cytokines in the mechanism of whole-body hyperthermia-induced cardioprotection. *Circulation.* 2000;102:452–457.

34. Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. *J Exp Med.* 1999;189:1699 –1706.